Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for atrial fibrillation
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients 30482761 2018 11 28 2473-9537 2 22 2018 Nov 27 Blood advances Blood Adv Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. 3193-3195 10.1182/bloodadvances.2018027078 Willmann Stefan S Clinical Pharmacometrics, Bayer AG, Wuppertal, Germany. Zhang Liping L Global Clinical Pharmacology
Periprocedural Outcomes of Direct Oral Anticoagulants vs. Warfarin in Non-Valvular Atrial Fibrillation: A Meta-analysis of Phase III Trials 29794081 2018 10 25 1524-4539 138 14 2018 Oct 02 Circulation Circulation Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. 1402-1411 10.1161/CIRCULATIONAHA.117.031457 Direct oral anticoagulants (DOACs) are surpassing warfarin as the anticoagulant of choice for stroke prevention in nonvalvular (...) atrial fibrillation. DOAC outcomes in elective periprocedural settings have not been well elucidated and remain a source of concern for clinicians. The aim of this meta-analysis was to evaluate the periprocedural safety and efficacy of DOACs versus warfarin in patients with nonvalvular atrial fibrillation. We reviewed the literature for data from phase III randomized controlled trials comparing DOACs with warfarin in the periprocedural period among patients with nonvalvular atrial fibrillation. Substudies from 4
Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery 30336826 2018 10 19 1558-3597 72 17 2018 Oct 23 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery. 2027-2036 S0735-1097(18)37078-5 10.1016/j.jacc.2018.07.088 The long-term risk of thromboembolism in patients developing new-onset post-operative atrial fibrillation (POAF) following noncardiac surgery (...) is unknown, and data on stroke prophylaxis in this setting are lacking. The purpose of this study was to assess the long-term risk of thromboembolism in patients developing new-onset POAF following noncardiac surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). Using Danish nationwide registries, the authors identified all patients who developed POAF following noncardiac surgery from 1996 to 2015. These were matched by age, sex, heart failure, hypertension, diabetes
Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study) 30025177 2018 10 25 1553-2712 2018 Jul 19 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study). 10.1111/acem.13522 We aim (...) to determine the benefit of two different doses magnesium sulfate (MgSO 4 ) compared to placebo in rate control of rapid atrial fibrillation (AF) managed in the emergency department (ED). We undertook a randomized, controlled, double-blind clinical trial in three university hospital EDs between August 2009 and December 2014. Patients > 18 years with rapid AF (>120 beats/min) were enrolled and randomized to 9 g of intravenous MgSO 4 (high-dose group, n = 153), 4.5 g of intravenous MgSO 4 (low-dose group, n
Usefulness of the CHA2DS2-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation 30342698 2018 10 21 1879-1913 2018 Sep 13 The American journal of cardiology Am. J. Cardiol. Usefulness of the CHA 2 DS 2 -VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With Atrial Fibrillation. S0002-9149(18)31761-2 10.1016/j.amjcard.2018.08.056 Sudden cardiac death (SCD), the most devastating (...) manifestation of ventricular arrhythmias (VAs), is the leading cause of mortality in patients with atrial fibrillation (AF). We hypothesized that the CHA 2 DS 2 -VASc score, consisting of age and several clinical risk factors, could be used to estimate the individual risk of SCD/VAs for AFpatients. From year 2000 to 2011, 288,181 newly-diagnosed AFpatients without antecedent SCD/VAs were identified from "Taiwan National Health Insurance Research Database." During the follow-up of 1,065,751 person-years
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report Gregory Y. H. Lip, MD; Amitava Banerjee, MD, DPhil; Giuseppe Boriani, MD, PhD; Chern en Chiang, MD, PhD; Ramiz Fargo, MD, FCCP; Ben Freedman, MD, PhD; Deirdre A. Lane, PhD; Christian T. Ruff, MD, MPH; Mintu Turakhia, MD; David Werring, PhD; Sheena Patel, MPH; and Lisa Moores, MD, FCCP BACKGROUND (...) : Theriskofstrokeisheterogeneousacrossdifferentgroupsofpatientswithatrial ?brillation (AF), being dependent on the presence of various stroke risk factors. We provide recommendations for antithrombotic treatment based on net clinical bene?t for patients with AFat varying levels of stroke risk and in a number of common clinical scenarios. METHODS: Systematic literature reviews were conducted to identify relevant articles published from the last formal search perfomed for the Antithrombotic and Thrombolytic Therapy: AmericanCollegeofChestPhysiciansEvidence
Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Background: The comparative safety and effectiveness of treatments to prevent thromboembolic complications in atrial fibrillation (AF) remain uncertain. Purpose: To compare the effectiveness of medical and procedural therapies in preventing thromboembolic events and bleeding complications in adults with nonvalvular AF. Data Sources: English-language studies in several databases from 1 (...) January 2000 to 14 February 2018. Study Selection: Two reviewers independently screened citations to identify comparative studies of treatments to prevent stroke in adults with nonvalvular AFwho reported thromboembolic or bleeding complications. Data Extraction: Two reviewers independently abstracted data, assessed study quality and applicability, and rated strength of evidence. Data Synthesis: Data from 220 articles were included. Dabigatran and apixaban were superior and rivaroxaban and edoxaban
Alternative drug may prevent atrial fibrillation following heart surgery Signal - Alternative drug may prevent atrial fibrillation following heart surgery Dissemination Centre Discover Portal NIHR DC Discover Alternative drug may prevent atrial fibrillation following heart surgery Published on 12 December 2017 After heart surgery around a third of people have atrial fibrillation, an abnormal heart rhythm, which impedes their recovery and lengthens hospital stay. Colchicine treatment could (...) reduce this complication by about a third. About 11 people would need this treatment to prevent one of them developing atrial fibrillation. Using amiodarone, an alternative drug commonly used in this situation, other research shows that about seven people would be treated to prevent one person suffering fibrillation. Colchicine is a drug licensed for the treatment of gout that combines both anti-inflammatory and heart rate control properties. As an older drug, it might be a cheaper alternative
Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Signal - Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Direct acting oral anticoagulants likely to be better than warfarin for people taking them for atrial fibrillation Published on 6 February 2018 In people with atrial fibrillation needing anticoagulant (...) treatment, deaths were fewer in those who had direct acting oral anticoagulants compared with warfarin. The picture is less clear for the risk of stroke and complications such as bleeding in the brain or gut. Apixaban had the best efficacy and safety profile and was cost-effective compared with warfarin. This study pooled the data in all trials reporting efficacy, safety and cost of anticoagulant prevention of stroke events in people with atrial fibrillation. Researchers used a technique called network
Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Signal - Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Dissemination Centre Discover Portal NIHR DC Discover Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Published on 18 July 2017 General practice software that generated screen reminders for patients with atrial fibrillation did not increase the proportion taking oral (...) anticoagulants appropriately by six months. This NIHR-funded trial included GPs in 47 surgeries in England and found that at the start only 63% of eligible patients with atrial fibrillation were being prescribed anticoagulants. Six months later the rate had increased to 66% in intervention practices and 64% in those following usual practice, a non-significant difference between the groups. Use of the software was associated with increased diagnosis of transient ischemic attack, which could be due to improved
Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Signal - Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Dissemination Centre Discover Portal NIHR DC Discover Rhythm control drugs after catheter ablation for atrial fibrillation give short-term but not long term benefits Published on 27 September 2016 When treating atrial fibrillation, short-term use of rhythm control (...) drugs after catheter ablation reduced the risk of abnormal heart rhythms in the three months after the procedure. They were of no benefit in preventing recurrence of atrial fibrillation in the longer term. Atrial fibrillation is a common abnormal heart rhythm that carries a high risk of stroke. Catheter ablation can be used to destroy the electrical pathways in the heart muscle that cause the abnormal rhythm, but recurrence is common. Several factors could influence the likelihood of abnormal
Chronic atrial fibrillation Chronic atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Chronic atrial fibrillation Last reviewed: September 2018 Last updated: October 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age. Patients frequently have co-existing cardiac or non-cardiac conditions, such as hypertension, coronary (...) strategy depends on the severity of symptoms, the duration of AF, and the presence of comorbid conditions. Treatment involves correction of the abnormal rate, or rate plus rhythm, along with anticoagulation in high-risk patients. Risks and benefits of a chosen therapy, such as rate control or rhythm control strategies utilising beta-blockers, calcium blockers, digoxin, anti-arrhythmic agents, catheter-based or surgical ablation for pulmonary vein isolation and left atrial substrate modification
Newer technologies for detection of atrial fibrillation. Atrial fibrillation is a common arrhythmia that is associated with increased risk of stroke, which can be reduced with appropriate anticoagulation treatment. However, it remains underdiagnosed in contemporary clinical practice using conventional detection methods, resulting in missed opportunities to implement appropriate treatment. Newer technologies developed in recent years can potentially enhance the detection of atrial fibrillation (...) and overcome certain limitations of the conventional methods. However, uncertainties remain about their use and the significance of atrial fibrillation detected by some of these newer technologies. This review examines the evidence supporting the use of some of these technologies and evaluates their applications in certain clinical scenarios.
Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project 30144238 2018 10 05 1742-1241 72 11 2018 Nov International journal of clinical practice Int. J. Clin. Pract. Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project. e13247 10.1111/ijcp.13247 Several clinical scoring systems have been derived to predict (...) the arrhythmia outcome of catheter ablation (CA) for atrial fibrillation (AF) but which is better is not clear. Simple clinical risk scores (that any clinician can use in the everyday clinic) can help assess the likelihood of recurrence of AFfollowing CA and the simple MB-LATER score has recently been described. We compare the predictive ability of seven existing clinical scoring systems (HATCH, CHADS 2 , CHA 2 DS 2 -VASc, BASE-AF2 , APPLE, CAAP-AF, and MB-LATER) in a Chinese cohort of AFpatients